Wall Street analysts are confident that Scribe Therapeutics can continue surging after going public less than a month ago. Three firms initiated coverage of the the gene-based therapeutics company. Wells Fargo assigned an overweight rating to Scribe Therapeutics. It also put a $60 price target on shares, implying 183% upside from Monday’s close. Leerink Partners gave it an outperform rating. The investment firm issued a $37 price target on shares, or about 75% above their previous closing price. Guggenheim put a buy rating on the stock and set a $50 price target on the stock, which is 136% higher the price at which shares last closed. “We initiate SCTX at OW … driven by a differentiated PCSK9 epigenetic silencing approach potentially offering years-long durability w/o permanent genetic modification, Wells Fargo analyst Yanan Zhu said Tuesday in a note. “We see [the first half of 2027] first-in-human data as [a] key value-driving catalyst.” Founded 2018, Scribe Therapeutics aims to use gene-editing technology to modify or remove DNA sequences in human cells, with the aim of lowering risk for cardiovascular and other diseases. It also specializes in leveraging epigenetic silencing, or the process of turning off genes, for therapeutic purposes. The company went public at the Nasdaq in late July. Its stock debuted at $15 per share, at the higher end of its expected share range. Since its IPO, Scribe Therapeutics has surged more than 44%, vastly outperforming the overall market. SCTX mountain 2026-07-23 Shares of Scribe Therapeutics are barely up since its IPO. The stock is likely to gain further ground by leveraging two of its own systems for gene-editing called X-Editor and Epigenetic Long-Term X-Repressor, according to Guggenheim. The systems are based on a naturally occurring enzyme that makes it relatively easier and more predictable to edit genes, according to Guggenheim. Beyond that, Scribe also has the advantage of being the only public company to have an epigenetic silencer in its clinic, giving it an edge over rivals in the development of gene-focused therapeutics, per Leerink Partners. “The company’s differentiated epigenetic silencing and gene editing platforms can drive meaningful shareholder value,” David Risinger, an analyst at Leerink, said Tuesday in a note to clients. “SCTX is developing a differentiated, clinical-stage CasX-based epigenetic silencer.”
